DOI:10.18643/gieu.2015.203
"> DOI:10.18643/gieu.2015.203
"> DOI:10.18643/gieu.2015.203
"/> Flibanserin – a challenging drug in the treatment of hypoactive sexual desire disorder
<- Home <- Arhive <- Vol. 11, Issue 4, December 2015



GINECOeu11(4)203-206(2015)
© gineco.eu


Flibanserin – a challenging drug in the treatment of hypoactive sexual desire disorder

M. Tampa, C. Mitran, M. Mitran, I. Sarbu, C. Matei, V. Benea, D. Navolan, T. Hangan, S. Georgescu


Abstract: Hypoactive sexual desire disorder (HSDD) is a condition characterized primarily by the decrease of sexual desire, affecting the quality of life. HSDD seems to be the most common sexual dysfunction in women. Therefore it should not be ignored, but treated. Recently the first drug for the treatment of HSDD, flibanserin, has been approved by FDA. Flibanserin is an agonist at 5-hydroxytryptamine (5HT1A) receptors and antagonist at 5HT2A receptors, acting also on dopamine receptors. It has been approved for premenopausal women but with certain restrictions. It was originally developed as an antidepressant drug, but studies have not supported its safety and efficacy. Its effect in HSDD was observed serendipitously. Studies conducted in North America and Europe have highlighted that flibanserin increases the number of satisfying sexual events and sexual desire, reducing the distress among premenopausal women.
DOI:10.18643/gieu.2015.203

Keywords: HSDD, sexual desire, flibanserin.

Full Text in PDF
© 2008-2024 gineco.eu. All rights reserved
created by if else factory